
The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to Axsome Therapeutics, Inc. (NASDAQ:AXSM) regarding its New Drug Application (NDA) for AXS-07 for the acute treatment of migraine.
The NDA is supported by results from Phase 3 MOMENTUM and INTERCEPT trials of AXS-07 in the acute treatment of migraine compared to placebo and active controls.